Clinical Trial

Combination of Ranibizumab and Targeted Laser Photocoagulation

Study acronym: CoRaLaII
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Intravitreal injections of Ranibizumab will be applied in all patients according to treatment guidelines. The experimental group will receive additional targeted laser photocoagulation of the peripheral areas of capillary non-perfusion (up to 4 laser treatments within 1st year of the study). Based on the long-term observation after CoRaLa I study an importantly shorter duration of treatment and a relevant reduction of the total number of re-injections in RL patients is expected.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-06-22; most recent amendment 2026-05-04.
Status change: Recruiting → Active, Not Recruiting 2026-05-04
Status change: Not Yet Recruiting → Recruiting 2020-10-06
Trial Details
NCT Number NCT04444492
Lead Sponsor University of Giessen
Collaborators: University of Leipzig
Conditions Central Retinal Vein Occlusion With Macular Edema
Enrollment 88 participants
Start Date 2020-08-25
Primary Completion 2027-11-30 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-08